Introduction
============

Diabetes mellitus (DM) is a common cause of excess mortality, approximately half of which results from cardiovascular diseases ([@b12-vhrm-4-1103]). The prevalence of DM is rising worldwide ([@b25-vhrm-4-1103]) and causing growing expenses for the health care system in addition to life-years lost.

Another disease causing excess cardiovascular mortality is familial hypercholes-terolemia (FH) ([@b1-vhrm-4-1103]). In FH, a hereditary low-density lipoprotein (LDL) receptor defect results, from birth, in impaired hepatic cholesterol uptake, which in heterozygotes leads to 2- to 3-fold higher blood cholesterol levels than normal. This results in accelerated atherosclerosis. The prevalence of heterozygous FH is 1/500 worldwide ([@b5-vhrm-4-1103]).

Both DM and FH are risk factors for atherosclerosis, which is associated with decreased arterial elasticity ([@b24-vhrm-4-1103]) in addition to plaque formation. Endothelial dysfunction, inflammation, fibrosis, and calcification of the arterial intima are the proposed mechanisms. Another mechanism leading to reduction in arterial elasticity is arteriosclerosis. This term associated with DM and aging refers to degradation of elastin, proliferation of collagen, and deposition of calcium in the media and adventitia in contrast to changes in the intima in atherosclerosis ([@b16-vhrm-4-1103]). These two mechanisms for loss of arterial elasticity often overlap ([@b16-vhrm-4-1103]), however, and the terms are sometimes confusingly interchanged.

Atherosclerosis of different vascular beds show positive association ([@b21-vhrm-4-1103]) and magnetic resonance imaging (MRI) is an established method to study vessel wall elasticity ([@b13-vhrm-4-1103]). In our previous study on young heterozygous FH patients carotid intima-media thickness (IMT) correlated with aortic elasticity markers (pulse wave velocity and complience) assessed with MRI ([@b20-vhrm-4-1103]).

Careful risk factor treatment, statins in particular ([@b17-vhrm-4-1103]), may slow down the atherosclerotic process or cause even regression of atherosclerotic lesions. The results of our earlier MRI studies on young (6 to 48 years of age) heterozygous FH patients and healthy controls are in line with this showing no difference between groups in aortic morphology and function ([@b20-vhrm-4-1103]) or brain lesions of vascular origin ([@b18-vhrm-4-1103]). The purpose of the present study was to assess the elastic properties of aorta with MRI in patients with more advanced FH disease. The results were compared with DM, in which aortic compliance is decreased due to arterio- and atherosclerosis ([@b16-vhrm-4-1103]). We also compared the aortic data to the carotid and femoral IMT, a measure of overall atherosclerosis, assessed with ultrasound (US).

Material and methods
====================

Patients
--------

The patient register of the North Karelia Central Hospital (Joensuu, Finland) contained data on 30 FH patients 48 to 64 years of age who had the same DNA-verified ([@b9-vhrm-4-1103]) North Karelia (NK) mutation in year 2003. The mutation produces similar phenotype (tendon xanthomas, 2--3-fold elevation in LDL cholesterol) like other receptor defective FH mutations. They also had coronary heart disease (CHD) verified from medical records and by physical examination. Eight of them were excluded because 3 also had DM, 1 had a body mass index (BMI) of 46, 2 had an unreliable diagnosis of CHD, 1 was unable to travel, and 1 was unreachable. Of the remaining 22 patients, 19 agreed to participate.

The same CHD criteria and the same patient register as for FH-NK patients was used to find 22 sex- and age-matched type 2 DM patients who had been treated at the department of internal medicine of the North Karelia Central hospital. Two were excluded because they did not use statin medication. Of the remaining 20 patients, 18 (aged 51--64) agreed to participate.

All FH-NK and DM patients used statin medication. See [Table 1](#t1-vhrm-4-1103){ref-type="table"} for their cardiovascular medication and characteristics. All FH-NK patients and 17 of the 18 DM patients had had AMI, a coronary bypass operation, or balloon angioplasty. Two DM and two FH-NK patients had each had transient ischemic attack (TIA), and one FH-NK patient had a history of ischemic stroke. No other patients had any history of neurological diseases.

The control group comprised 30 controls (aged 49--63) recruited among acquaintances of the Helsinki Medical Imaging Center (Helsinki, Finland) staff. None of the controls had CHD, DM, or history of any vascular or neurological disease. One control was excluded because of Moya-Moya disease detected in brain MRI.

A medical ethics committee approved the study with informed consent obtained from all subjects.

MRI
---

MRI was performed with a 1.5T Siemens Sonata imager (Erlangen, Germany) with a phased array coil. A breath-hold oblique sagittal TSE sequence (TR/ TE/ Flip Angle/ FOV/Matrix/ Slice Thickness = 47/ 1.6/ 65 /298\*340/148\*256/6) of the aorta was taken to assess the imaging planes for the cine sequence (TR/ TE/ Flip Angle/ FOV/ Matrix /Slice Thickness = 28/3.2/30/223\*340/156\*256/5) taken at the level of the right pulmonary artery and at the level of the renal artery. Time resolution was 28 ms.

Electrocardiogram gating was used with all sequences. Due to poor image quality, one DM patient and one control were excluded from analysis of compliance of the ascending aorta and descending thoracic aorta, and one FH patient was excluded from descending abdominal aorta measurement.

The images were analyzed with Siemens Leonardo workstation's Argus software (Erlangen, Germany) by S.S. who was blinded to the clinical and laboratory data and had 5 years of experience with the measurements. Compliance (%/mmHg) was calculated from the cine images by the equation: (\[Amax-Amin\]/Amin\*100)/(Ps-Pd), where Amax = maximum luminal area, Amin = minimal luminal area, Ps = systolic blood pressure, and Pd = diastolic blood pressure ([@b11-vhrm-4-1103]).

Ultrasound
----------

One experienced radiologist (K.L.) performed all ultrasound examinations with an 8--12 Mhz linear transducer. The subjects were examined in the supine position. IMT was measured with high-resolution B-mode ([@b14-vhrm-4-1103]) for the far wall of each common carotid artery 1 cm below the bifurcation, and of the left femoral artery at the level of the inguinal ligament, and the mean of 3 consecutive measurements was calculated. The carotid bifurcations and the left femoral artery were examined for plaques. Doppler flow measurements were performed to assess the severity of arterial stenoses caused by the plaques. Stenosis of 70% or more was considered significant ([@b6-vhrm-4-1103]). Ultrasound data for two controls were unavailable.

Laboratory tests
----------------

After overnight fasting, each subject provided a venous blood sample. Serum total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, fasting glucose, glycosylated hemoglobin, homocysteine, liproprotein a, insulin, and high-sensitivity C-reactive protein (hsCRP) were determined by standard methods. The LDL cholesterol value was calculated by the Friedewald formula. To take into account each participant's lifelong cholesterol burden, we calculated the cholesterol-years score, as suggested by [@b7-vhrm-4-1103]. Blood pressure was measured twice with an automatic meter from the left arm of the patient lying supine, with the mean of two measurements used in the calculations. One control was excluded from laboratory assessments because her anti-inflammatory therapy was started between the MR examination and laboratory tests. Because infections can elevate CRP level beyond that associated with inflammation in cardiovascular diseases ([@b15-vhrm-4-1103]), 4 DM patients whose hsCRP levels exceeded 10 mg/L were thus excluded from CRP analysis.

Statistical methods
-------------------

Variables between the groups (controls, FH, and DM patients) were compared with ANOVA or the Kruskal-Wallis test, as appropriate. A *P*-value \< 0.05 was considered statistically significant.

Results
=======

MRI
---

DM patients had significantly less compliant descending thoracic and abdominal aorta than did controls, but this difference did not reach significance in ascending aorta. No significant difference existed between FH-NK and DM patients ([Figure 1](#f1-vhrm-4-1103){ref-type="fig"}).

Ultrasound
----------

In all vessels, IMT appeared significantly greater in the FH-NK and DM patients than in the controls ([Figure 2](#f2-vhrm-4-1103){ref-type="fig"}). No significant differences appeared between FH-NK and DM patients. Carotid or femoral plaques appeared in 15 (79%) FH-NK and in 10 (56%) DM patients. Only one control had a plaque, and it was in femoral artery ([Figure 3](#f3-vhrm-4-1103){ref-type="fig"}). Five FH patients showed stenosis, occlusion or both in carotid arteries: four showed stenosis, the left internal carotid artery was occluded in one, and another had occlusion of the right internal carotid artery. None of the DM patients or controls showed significant stenosis or occlusion.

Laboratory tests
----------------

Cholesterol-years score and total and LDL cholesterol level of the FH-NK patients were greater than those of DM patients and controls. DM patients had higher trigycerides, fasting glucose, insulin, percentage of glycosylated hemoglobin, homocysteine, and hsCRP than did FH-NK patients and controls ([Table 2](#t2-vhrm-4-1103){ref-type="table"}).

Discussion
==========

Compliance of the descending aorta was lowest in the DM patients and highest in controls, but no significant difference emerged between FH and DM patients. Carotid and femoral IMT of DM and FH patients was greater than that of the controls, with no difference between IMT of FH and DM patients. Only the FH patients had significant carotid stenoses or occlusions; they also had more plaques than either DM patients or controls.

Our obese DM patients had compliance of the descending aorta lower than that of controls. This is in concordance with a recent MRI study showing lower aortic elasticity than in their 16 controls in 14 type 2 DM patients averaging 55 years of age and without any complications ([@b23-vhrm-4-1103]). In addition, decreased aortic elasticity appeared in the MRI of 21 healthy obese (BMI \> 30) men compared to 25 lean (BMI 19--25) controls ([@b3-vhrm-4-1103]), all 20 to 40 years old. The aortic compliance of our FH patients was lower than in controls, although their difference was not significant. This is in line with an aortic MRI study on 10 relatively young (34 years old on average) asymptomatic heterozygous FH patients with no difference in compliance compared to that of controls ([@b22-vhrm-4-1103]) and with our earlier study on healthy 6- to 48-year-old FH patients with no difference in aortic compliance compared to that of controls ([@b20-vhrm-4-1103]). Our FH patients with verified CHD were expected to have decreased aortic compliance, as CHD is associated with lower aortic elasticity ([@b11-vhrm-4-1103]; [@b4-vhrm-4-1103]). Their improved risk-factor treatment, statin treatment in particular, may have had beneficial effects on compliance, an effect shown in one MRI study of 64 hypercholesterolemic patients ([@b4-vhrm-4-1103]).

The carotid and femoral IMT of our DM and FH patients was higher than that of the controls as expected. Our FH patients had more carotid and femoral plaques than did DM patients or controls. Only the FH patients had occlusions and significant stenoses of carotid arteries suggesting the most advanced atherosclerosis. In the atherosclerotic process, an increase in IMT precedes plaque formation ([@b27-vhrm-4-1103]). While statins cause regression of atherosclerotic lesions ([@b17-vhrm-4-1103]) and calcifications ([@b2-vhrm-4-1103]; [@b26-vhrm-4-1103]), to our knowledge, information is lacking on their effect on severely stenosed arteries. CHD duration was longer in our FH than DM patients ([Table 1](#t1-vhrm-4-1103){ref-type="table"}). The reason for a higher number of plaques in our FH patients may be their long exposure to high cholesterol concentrations, before statin treatment in the late 1980's became available. In addition, the current cholesterol levels of our FH patients exceeded those of the DM patients despite statin treatment ([Table 2](#t2-vhrm-4-1103){ref-type="table"}). Furthermore, before statin treatment, FH patients showed a risk for strokes over 20-fold compared to general population ([@b8-vhrm-4-1103]). Statins provide effects beyond cholesterol lowering ([@b10-vhrm-4-1103]), ones which may stabilize atherosclerotic plaques and prevent strokes and other atherothrobotic events. Our FH patients showed no more brain lesions than did controls ([@b19-vhrm-4-1103]).

The major limitation of our study is the relatively small number of patients and controls. This may explain why no significant difference was found in compliance between FH patients compared to DM patients and controls.

We conclude that compliance of the descending aorta was lowest in DM patients and highest in controls, with no significant difference between FH and DM patients. Carotid and femoral IMT was greater in FH and DM patients than in controls. FH patients had more plaques and were the only ones with stenoses in carotid arteries. We theorize that the differences between FH and DM reflect the differences between athero- and arteriosclerosis. Furthermore, the plaque status of FH patients suggests that they are probably more prone to thromboembolic complications of atherosclerosis than are DM patients; their statin treatment, however, may lower the risk. Due to small sample size, larger studies are needed to confirm the findings since arterio- and atherosclerosis are overlapping processes.
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**Note:** Bars indicate mean, whiskers ± SD.\
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###### 

Characteristics and cardiovascular medication of controls, DM, and FH-NK patients

                                   DM (n = 18)   FH-NK (n = 19)   Controls (n = 29)   *P*-value
  -------------------------------- ------------- ---------------- ------------------- ------------------------------------------------------
  Males/females, no.               11/7          11/8             13/16               
  Age, y                           57.9 ± 3.7    55.9 ± 4.5       56.0 ± 3.8          0.210
  BMI, kg/m^2^                     32.6 ± 4.8    26.7 ± 2.8       25.9 ± 3.5          0.000 (DM \> FH; DM \>CTRL; FH = CTRL)
  Systolic blood pressure, mmHg    143 ± 21      137 ± 23         130 ± 14            0.081
  Diastolic blood pressure, mmHg   83 ± 13       78 ± 10          79 ± 9              0.179
  Statin usage, y                  5.2 ± 2.9     15.1 ± 1.3       0                   0.000**[a](#tfn2-vhrm-4-1103){ref-type="table-fn"}**
  Duration of CHD, y               5 ± 3.1       13.3 ± 7.6       0                   0.000**[a](#tfn2-vhrm-4-1103){ref-type="table-fn"}**
  Statins, users                   18            19               0                   
  Beta blockers, users             18            18               1                   
  vAcetylsalicylic acid, users     16            17               0                   
  ARB or ACE inhibitors, users     11            3                0                   
  Smokers                          3             3                0                   

**Notes:** Values are means ± SD unless otherwise stated.

^a^FH and DM groups compared.

**Abbreviations:** DM, diabetes mellitus; FH-NK, familial hypercholesterolemia-North Karelia; BMI, body mass index; CHD, coronary heart disease; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers.

###### 

Laboratory data on controls and DM, and FH-NK patients

                                      DM (n = 18)   FH-NK (n = 19)   Controls (n = 28)   P-value
  ----------------------------------- ------------- ---------------- ------------------- ------------------------------------------
  Total cholesterol, mmol/L           4.7 ± 0.9     6.0 ± 1.0        5.6 ± 0.8           0.000 (DM \<FH; DM \< CTRL; FH \> CTRL)
  LDL cholesterol, mmol/L             2.5 ± 0.7     4.1 ± 0.9        3.3 ± 0.7           0.000 (DM \< FH; DM \< CTRL; FH \> CTRL)
  HDL cholesterol, mmol/L             1.2 ± 0.2     1.4 ± 0.3        1.7 ± 0.4           0.000 (DM = FH; DM \< CTRL; FH \< CTRL)
  Triglycerides, mmol/L               2.1 ± 0.9     1.2 ± 0.4        1.4 ± 0.6           0.001 (DM \> FH; DM \> CTRL; FH = CTRL)
  Cholesterol-years score, mmol-y/L   368 ± 89      516 ± 96         313 ± 58            0.000 (DM \< FH; DM = CTRL; FH \> CTRL)
  Fasting glucose, mmol/L             8.7 ± 3       5.2 ± 0.6        5.1 ± 0.4           0.000 (DM \> FH; DM \> CTRL; FH = CTRL)
  Insulin, mU/L                       31.1 ± 31.4   7.5 ± 3.7        6 ± 4.5             0.000 (DM \> FH; DM \> CTRL; FH = CTRL)
  Glycosylated hemoglobin, %          8.2 ± 1.6     5.7 ± 0.2        5.9 ± 0.3           0.000 (DM \> FH; DM \> CTRL; FH = CTRL)
  Lipoprotein a, g/L                  0.22 ± 0.21   0.20 ± 0.21      0.21 ± 0.20         0.359
  Homocysteine, μmol/L                15 ± 3        12.2 ± 2.5       13.1 ± 4.8          0.047 (DM \> FH; DM = CTRL; FH = CTRL)
  HsCRP, mg/L                         3.07 ± 2.45   2.22 ± 2.34      1.35 ± 1.92         0.001 (DM \> FH; DM \> CTRL; FH = CTRL)

**Note:** Values are means ± SD.

**Abbreviations:** DM, diabetes mellitus; FH-NK, familial hypercholesterolemia-North Karelia; CTRL, control; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HsCRP, high-sensitivity C-reactive protein; SD, standard deviation.
